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https://doi.org/10.1016/j.stemcr.2018.08.013SUMMARYReproducibility in molecular and cellular studies is fundamental to scientific discovery. To establish the reproducibility of a well-defined
long-term neuronal differentiation protocol, we repeated the cellular and molecular comparison of the same two iPSC lines across
five distinct laboratories. Despite uncovering acceptable variability within individual laboratories, we detect poor cross-site reproduc-
ibility of the differential gene expression signature between these two lines. Factor analysis identifies the laboratory as the largest source
of variation along with several variation-inflating confounders such as passaging effects and progenitor storage. Single-cell transcrip-
tomics shows substantial cellular heterogeneity underlying inter-laboratory variability and being responsible for biases in differential
gene expression inference. Factor analysis-based normalization of the combined dataset can remove the nuisance technical effects,
enabling the execution of robust hypothesis-generating studies. Our study shows that multi-center collaborations can expose
systematic biases and identify critical factors to be standardized when publishing novel protocols, contributing to increased cross-
site reproducibility.INTRODUCTION
Reproducibility is a cornerstone of science. Yet, in recent
years, a number of publications highlighted serious issues
regarding this fundamental principle of scientific
approach, to the extent that the expression ‘‘reproduc-
ibility crisis’’ was coined (Munafo` et al., 2017; Baker,
2016). The more complex experimental procedures are,
and the longer they are applied, the higher the possibility
of introducing variability and noise during a research
study. This is particularly critical for human induced
pluripotent stem cells (iPSCs), which need to be differenti-
ated using lengthy complex procedures in order to be used
as novel in vitromodels in basic science and drug discovery
(Avior et al., 2016), but this increases the variability, such as
well-to-well differences in cell density and cellular hetero-Stem Cell R
This is an open access article under the Cgeneity. Protocols for efficient generation of specific
neuronal subtypes mimic human development both in
the appearance of successive phenotypes, and also in dura-
tion, potentially taking more than 100 days in vitro (Shi
et al., 2012a). Reproducibility is especially critical when
comparing iPSC-derived cells from multiple donors to
discover cellular disease phenotypes and their underlying
pathways using unbiased omics experiments. While the
reproducibility of transcriptomic (Li et al., 2014) and prote-
omic (Kim et al., 2007) approaches have been well estab-
lished for simple cellular systems, no systematic studies
have been performed to assess the cross-site reproducibility
of these readouts after a long-term iPSC differentiation pro-
tocol, such as the derivation of human cortical neurons.
The goal of our study was to identify the extent of vari-
ability in an iPSC experiment conducted by multipleeports j Vol. 11 j 897–911 j October 9, 2018 j ª 2018 The Authors. 897
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groups of the IMI StemBANCC (Innovative Medicines
Initiative, Stem cells for biological assays of novel drugs
and predictive toxicology) initiative, which aims to
generate and interrogate a large collection of stem cell
models for disease modeling and therapeutic research. For
multi-site comparative studies, large public-private part-
nerships offer a unique framework due to the participation
of both academic and industry organizations with strong
scientific background in iPSC biology, representing a
‘‘best case scenario’’ to assess cross-site reproducibility.
Our cross-site analysis utilized a previously published
neuronal differentiation protocol (Shi et al., 2012b). In
this study we set out to assess the inter- and intra-labora-
tory reproducibility of transcriptomic and proteomic read-
outs using two iPSC lines and standard laboratory practices
adhered to by all participating laboratories. The differenti-
ation protocol nevertheless enables individual laboratories
to apply their laboratory-specific approaches simulating
the reproduction of a publishedmethod. The key questions
in this studywere firstlywhether a laboratorywould be able
to separate the two iPSC lines at the molecular level, and
secondly whether the identified molecular differences be-
tween the two lines were consistent between laboratories.
Three academic and two industrial organizations partici-
pated in the study to simulate this real-life reproducibility
scenario. In addition to bulk omics analyses and single-
cell (SC) RNA sequencing (RNA-seq) to assess cellular
heterogeneity, the reproducibility of a known cellular
phenotype arising from a specific mutation in one of the
iPSC lines has also been evaluated.
To our knowledge, this study represents the first compre-
hensive experiment to assess the intra- and inter-labora-
tory reproducibility of multiple readouts measured in an
iPSC-derived in vitro model system containing differenti-
ated human neurons. Despite acceptable intra-laboratory
reproducibility of omics readouts and surprisingly good
cross-site reproducibility of a previously identified cellular
phenotype, omics datasets from different sites have large
variation that masks specific differences, rendering it
impossible to distinguish these two lines from each other
in a combined dataset. SC analyses demonstrate that cell-
type heterogeneity is an important confounder in these
comparisons, with variation undermining the detection
of differentially expressed (DE) genes, proteins, and path-
ways. However, we show that there are identifiable sources
of variation that investigators can control and thereby in-
crease biological signals in iPSC-based molecular studies.
Besides strongly recommending to disclose these identified
variation-inflating confounders in published iPSC differen-
tiation protocols, our study also shows that collaborative
approaches with larger sample numbers in cross-laboratory
studies are valuable to detect and remove unwanted varia-
tion (Freytag et al., 2015).898 Stem Cell Reports j Vol. 11 j 897–911 j October 9, 2018RESULTS
Experimental Design
Five laboratories (referred as A, B, C, D, and E) received the
same two fibroblast-derived human iPSC lines. One line
was derived from a healthy control individual while
the second one originated from a patient with familial
Alzheimer’s disease carrying a presenilin 1 (PS1) mutation.
Note that our study was not designed to examine the
effects of this mutation per se but instead focusses on the
reproducibility of the comparison of these two lines (see
Discussion). All laboratories followed the same standard
operating protocol (SOP) (see Supplemental Experimental
Procedures) to differentiate the cultures into cortical
projection neurons in three independent inductions (repli-
cates) (Figure 1). Laboratory-specific variations and obser-
vations were recorded (see below and Table S1). Total
RNA and cell lysates were collected at two time points dur-
ing differentiation, specifically, after 25 and 55 days from
the final plating (FP), respectively (representing 50 and
80 days in vitro differentiation from the iPSC state), and
sent to central locations for RNA-seq and proteomic ana-
lyses (Figure 1A).Molecular Profiles Show Strong Similarity within
Laboratories and Clearly Separate by Cell Line
Genotype
To assess the reproducibility of transcriptomic readouts we
first examinedwhether each laboratory was able to demon-
strate a clear segregation between the two iPSC lines at a
molecular level. Detection of differential molecular profiles
between the two lines might be expected due to their
differing genetic and epigenetic backgrounds. It is impor-
tant for molecular studies of iPSC-based models that geno-
typic differences between lines are identifiable.
Applying RNA-seq, the expression of variable numbers of
protein-coding genes across different samples were de-
tected (with at least one count), with about 70% (13,373)
of the 19,086 protein-coding genes expressed across all 57
samples. In further analyses we considered only this set
of 13,373 commonly expressed genes. Principal-compo-
nent analysis (PCA) on the transcriptomic profiles from
individual sites illustrated clear separation between the
samples from the two cell lines in all five laboratories at
both early and late time points (Figure 2A), indicating
that genetic background or genotype is a clear source of
variation within laboratories. Each laboratory performed
three independent cortical differentiations, and the consis-
tency within each laboratory is evident by the greater sim-
ilarity in gene expression profiles of the three replicates of
the same genotype compared with the gene expression
profiles between genotypes (Figure 2A). The Euclidean
Figure 1. Experimental Outline of the Study
(A) iPSC lines from two genotypes were differentiated at five different sites with three individual inductions at each site. The given samples
were taken at FP (final plating) + 25 days and FP + 55 days.
(B) Representative iPSC-induced cortical neurons at FP + 10 days in culture, immunolabeled with Tuj-1 (green) and DAPI (blue) derived
from SBAD3 and AD SB808 cell lines. Neurons grown in two different laboratories are shown (sites D and B). Scale bars, 50 mm (site D),
100 mm (site B).
(C) Cortical neuronal inductions from CTR and PS1 cells 10–20 days after FP, showing presence of neuron-specific bIII-tubulin (green) for
sites B, C, D, and E or MAP2 (green) for site A and nuclear marker DAPI (blue). Scale bars, 100 mm (site A); 100 mm (site B); 100 mm (site C);
50 mm (site D); 100 mm (site E).
(D) Heatmaps of gene expression (log10[fragments per kilobase of transcript per million mapped reads]) at the two time points (FP + 25
left and FP + 55 right) of cortical neuron markers, hindbrain markers, and pluripotency markers for 57 StemBANCC samples confirm the
presence of expected neuronal markers and the absence of all but SOX2 non-neuronal markers.
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Figure 2. Detection of Laboratory as One Source of Unwanted Variability
(A) Individual laboratory experiments separate by cell line. PCAplotswithin laboratory (sites A–E)on13,373genes expressed across all samples
(normalized gene counts were used) show clear separation between the samples from the two cell lines at both early and late time points.
(B) Degree of variability between replicates within the same laboratory. Boxplots showing the coefficients of variation calculated between
gene expression values across replicates within each laboratory, cell line, and time point. Box-and-whisker graphs represent distributions,
where the span of the box is the interquartile range (IQR) and includes the median (bold line). The ends of the upper and lower whiskers
represent the data point with the maximum distance from the third and first quartiles, respectively, but no further than 1.5 3 IQR. Data
beyond the end of the whiskers are outliers.
(C) Samples cluster by laboratory in a combined PCA. First two principal components from a PCA on gene expression of 13,373 protein-
coding genes that are expressed in all samples clearly cluster samples based on laboratory of origin.
(D) Laboratory and cell count are major confounders in protein-based PCA. First two principal components from a PCA on 1,034 proteins
expressed across all samples; color coding according to laboratory; shapes correspond to cell line and sizes to averaged cell count.
See also Figure S1.distances calculated between the gene expression profiles
of each sample show that, within each laboratory, the
expression profiles derived from replicates of the same
line are significantly closer to each other than those be-
tween replicates of different lines for four out of five labora-
tories (Figure S1A).
The power to identify DE genes is strongly dependent on
the experimental variance. A measure of this variance, the
coefficient of variation (CV) of the transcriptomic dataset
varied between laboratories. While the CV showed no clear
genotype or maturation time trends (Figure 2B), the
differing CV for each laboratory resulted in a large differ-900 Stem Cell Reports j Vol. 11 j 897–911 j October 9, 2018ence in the number of DE genes between genotypes
controlling for time point variation (Figure S1B). Unsur-
prisingly, the highest number of DE genes was found in lab-
oratory D, which shows the lowest degree of dispersion
between replicates.
Cross-Site Comparison of Molecular Profiles Show
Poor Reproducibility
Having demonstrated that each laboratory exhibited a
clear segregation based on gene expression profiles, we
asked whether the molecular differences were consistent
between laboratories. Despite the use of a detailed SOP, in
a combined dataset containing data from all five partners,
we found the laboratory was the dominant source of varia-
tion, masking any genotypic effects (Figure 2C). Impor-
tantly, only 15 DE genes are found in common between
all laboratories indicating a remarkably low degree of
cross-laboratory reproducibility (Figure S1B). The low num-
ber of overlapping genes may be a consequence of three
laboratories (A, B, and E) detecting only a small number
of DE genes. Certainly, sites C and D, which had the lowest
CV and the highest number of DE genes, showed
about 50% overlap. At the pathway level, the similarity
in enriched gene ontology (GO) terms for these five lists
of DE genes is highly variable with semantic similarity
comparison values ranging from 0.36 to 0.64 (Figure S1B).
In summary, despite extensive efforts to replicate the same
experiment, we observe significant variation that would
confound any inter-laboratory comparison.
The PCA plot (Figure 2C) and the heatmap of Spearman’s
correlations (Figure S1C) revealed three potential outliers
(SB808 line, laboratory C, here specific issues with detach-
ment of cellmonolayerwere observed, see Table S1 onmeta-
data). Nevertheless, in general, recorded variation in exper-
imental procedures noted by individual laboratories did not
explain the detected cross-laboratory sample variability
(Figure S1C). The above observations suggest that much of
the inter-laboratory variation arises from additional con-
founders that increase the within-laboratory variance.
To investigate whether cross-site variability in gene
expression was also present at the proteomic level, lysates
from replicate wells of the same 57 samples were pooled
and analyzed (see Experimental Procedures). Similarly to
the transcriptomic samples, the low number of overlap-
ping proteins detected across all samples (only 10% of
the 10,483 proteins observed in at least one sample) indi-
cated that the abundance of various proteins is highly var-
iable. For further analyses, we retained only those 1,037
proteins that were observed in all samples. As observed
for the transcriptomics data, PCA and heatmap of Spear-
man’s rank correlations of protein abundances did not
show clustering of samples by genotype (Figures 2D and
S1D). We noticed that, despite normalizing for total pro-
tein, the first principal component clearly captures a strong
cell-number-related effect in addition to a laboratory-
dependent effect. Taken together, the transcriptomic and
proteomic profiles demonstrated a strong inter-laboratory
variation that masks variation due to the genetic back-
ground of each iPSC line.
Factor Analysis Reveals the Transcriptional Axis of
Maturation in iPSC-Derived Neurons and Confirms
Robust Cortical Neuronal Differentiation
It is evident that cross-site comparisons can be significantly
hampered by site-specific confounders, but collaborativestudies that generate a large number of samples can have
the power to identify nuisance technical effects. We
applied a factor analysis-based method called remove un-
wanted variation (RUV) (Risso et al., 2014). This method
can capture nuisance technical effects and RUV in the
form of factors, while retaining variation associated with
the biological covariate of interest. To demonstrate the util-
ity of factor analysis in revealing biological signals, we first
used the approach to determine the transcriptional deter-
minants of in vitro neuronal maturation, exploiting the
two time points, FP + 25 and FP + 55, in our samples.
Consistent with the reported fetal nature of neurons
derived from pluripotent stem cells (Handel et al., 2016),
hierarchical clustering of the bulk transcriptomic profiles
of 57 samples demonstrated their overall similarity to fetal
postmortem brain samples from the BrainSpan Atlas of the
DevelopingHumanBrain (Sunkin et al., 2013) (Figure S2A).
We performed normalization using RUVon samples from a
single line (see Supplemental Experimental Procedures) to
expose a clear time point variation that was not masked
by any cell line-dependent effect on maturation.
PCA of the RUV-normalized gene expression profiles
showed clustering of samples by time points (Figure 3A).
BrainSpan samples projected onto the PCA coordinates of
normalized iPSC neuron-maturity expression profiles reca-
pitulated the direction of human neuronal maturation
(Figure 3A) better than those projected onto PCA coordi-
nates of non-normalized gene expression levels (Fig-
ure S2B). Accordingly, the post-RUV expression signature
clearly separated the early and late stages of differentiation
in BrainSpan fetal samples, and is in line with the observed
direction ofmaturation in our samples. To confirm aneuro-
developmental role for genes whose expression varies in
this component space, we selected those genes that maxi-
mally contributed in either direction to the identified tran-
scriptional axis of maturation (principal component one)
with a gene loading on this axis greater/less than ±0.01.
To validate the biological role in neuronal maturation of
the contributing genes, we used the CORTECON dataset
(van de Leemput et al., 2014), which identified gene clus-
ters representative of changes in temporal gene expression
of in vitro cerebral cortex development fromhuman embry-
onic stem cells.We observed that the genes characteristic to
the less mature stage in STEMBANCC samples (with posi-
tive scores on PC1)were enriched inCORTECONgene clus-
ter specific to the early developmental stages, namely the
‘‘cortical specification’’ cluster and that are active from
days 10 to 20 after differentiation (van de Leemput et al.,
2014). The set of genes representing the more mature stage
(with negative scores on PC1) was instead significantly en-
riched in the ‘‘upper layer generation’’ cluster with an
expression peak from day 60, as expected (Figure 3B).
This analysis also confirmed that the laboratories wereStem Cell Reports j Vol. 11 j 897–911 j October 9, 2018 901
Figure 3. RUV-Corrected Gene Expression
Reveals Differences of Maturation in Data
(A) Identification of a transcriptional axis of
neuron maturation. BrainSpan samples are
projected on the principal components
calculated on the gene expression data in the
present study, after RUV correction. It can be
seen that the principal components of gene
expression separate both STEMBANCC and
BrainSpan samples based on developmental
stages.
(B) Genes contributing to the identified
transcriptional axis of neuron maturation are
consistent with external data. The bar plot shows the percentages of time point-specific genes (selected based on gene loadings from PCA
of the samples after RUV correction) falling into each CORTECON gene cluster representative of neuron developmental stages: 25-day-
specific genes are enriched in pluripotency (PP), neuron development (ND), and cortical specification (CS) clusters; 55-day-specific genes
are enriched in deep layer neuron generation (DL) and upper layer neuron generation (UL) clusters.
See also Figure S2.successful with their differentiation protocol in producing
cells with cortical specification at the early stage and upper
layer cortical neurons as expected with this protocol at the
later stages.
Factor Analyses Reveal Genotype-Related Differential
Molecular Expression
To examine the sources of experimental variation, we
applied RUV across all samples, retaining both cell line
and time point variations. After RUV correction of gene
counts on the first five estimated factors of variation, sam-
ples in the combined dataset cluster clearly by cell line and
by time point (Figure 4A). Consequently, the number of DE
genes detected between the 2 iPSC lines across all samples
combined increased (from 1,873 before RUV correction to
3,051 after RUV correction) and between time points
(from 2,186 before RUV correction to 3,868 after RUV
correction) across all samples (see Table S2 for a complete
list of DE genes). Examining a set of neuron-specific stage
markers that are expected to be expressed in the differenti-
ating samples (see Supplemental Experimental Proced-
ures), the large distributional differences that were evident
between samples in the non-normalized data (Figure 4C,
top) were reduced upon removal of the identified variance
factors (Figure 4C, bottom).
Similar to the transcriptomic analysis, when RUV correc-
tion was applied to protein abundances (available for
FP + 55 time point only), good separation between the
two iPSC lines was observed. After this normalization, a
combined PCA shows that both transcriptomic and prote-
omic samples cluster together by iPSC line, indicative of a
correlation between the two data types (Figure 4B). This is
further supported by the increase in the number of differ-
ential abundant (DA) proteins (0 before RUV correction,
205 after RUV correction) and consequently in the percent-902 Stem Cell Reports j Vol. 11 j 897–911 j October 9, 2018age of overlapping DE genes and DA proteins between lab-
oratories after RUV correction (0% before RUV correction,
14% after RUV correction).
To study further the effect of RUV on the reproducibility
across laboratories, we measured the extent of homogene-
ity between laboratories in evaluating the same biological
effect (see Supplemental Experimental Procedures). The
number of genes showing high heterogeneity across all
samples (I2R 75%) decreased as a function of the number
of RUV factors that are regressed out from the data (from
6,443 genes before RUV correction to 584 genes after
RUV correction on 20 factors, Figure 5A, top). In addition,
an increase in overlapping DE genes between cell lines
across laboratories was also observed (from 15 before RUV
to 243 after RUV correction on 20 factors, Figure 5A, mid-
dle; Table S3). The post-RUV PCA plots for each laboratory
clearly reveal that the segregation by both time point and
genotype is more evident than pre-RUV (Figure 5B). The
I2 measure and variance analysis at the gene expression
level before RUV and after RUV (Figures 5A, top and S3)
confirm that the laboratory-dependent source of variation
was properly removed from the data to expose the varia-
tion of interest. Thus, given sufficient power, technical
variability, including hidden laboratory-dependent varia-
tion, can be corrected and enables detection of the biolog-
ical signal.
Identification of Experimental Variables Inflating
Gene Expression Variance
We next examined the known and investigator-recorded
covariates that correlated with the RUV factors. As ex-
pected, the variable ‘‘SITE’’ explained 60%, 40%, 38%,
and 39% of the variance in factors 1, 2, 3, and 4, respec-
tively (Figure 5C). The second most contributing source
of variation captured by RUV was attributable to starting
Figure 4. Impact of Unwanted Variance Removal by RUV Correction
(A) RUV separates sample gene expression profiles by cell line and time point. First two principal components from a PCA on gene
expression over all samples after RUV correction.
(B) RUV separates sample gene expression and protein abundance profiles by cell line. First two principal components from a ‘‘second’’ PCA
on both pooled gene and protein expression adjusted for PC1 of ‘‘first’’ PCA. This first PC1 captures the differences between protein and gene
expression, therefore adjustment makes the two datasets more comparable. Gene expression values and protein abundances are RUV
corrected separately on the two datasets for FP + 55 time point.
(C) RUV normalizes the expression of marker genes expected to be similarly expressed across all samples. Gene expression on log scale of
gene markers of three neuron-specific stages before (top row) and after RUV correction (bottom row). Box-and-whisker graphs represent
distributions, where the span of the box is the interquartile range (IQR) and includes the median (bold line). The ends of the upper and
lower whiskers represent the data point with the maximum distance from the third and first quartiles, respectively, but no further than
1.5 3 IQR. Data beyond the end of the whiskers are outliers.the experiment on different days for technical replicates
(15%, 22%, 20%, and 38% of the variance in factor 1, 3,
7, and 13, respectively; Figure 5C). In general, the propor-
tions of variance in RUV factors that could be explained
by the remaining candidate confounders were moderate
to low. Among these, 18% and 15% of variance in factors
2 and 3, respectively, were explained by differences in cell
counts.As SITE was the strongest cause of variability, we attemp-
ted to correlate SITE-specific variation in RUV factors to
particular experimental effects by fitting linear models re-
gressing site-specific RUV means outputted from the vari-
ance component analysis on each site-specific metadata
variable in turn. Several covariates, namely iPSC passage
number before differentiation and the number of passages
before FP,media volume changes, feeding at weekends, andStem Cell Reports j Vol. 11 j 897–911 j October 9, 2018 903
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use of frozen neural progenitor cells, were highly correlated
with several factors (Figure 5D).
We also examined the variation underlying expression at
the gene-specific level by fitting a regression model
(MCMCglmm) (Hadfield, 2010) between gene counts and
the known covariates. The analysis enabled the identifica-
tion of genes that may underlie the covariate. The top
100 genes related to ‘‘DETACHMENT’’ were enriched in
GO terms related to regulation of cell cycle, apoptosis,
and DNA metabolism, while those similarly associated
with ‘‘CELL_COUNT’’ are enriched in cellular respiration
and lipid metabolism pathways, and those genes related
to ‘‘TIME_POINT’’ were involved mainly in neuron differ-
entiation processes (complete lists of GO terms in Table S4).
Cell Type Heterogeneity Is a Major Source of Inter-
laboratory Variation
Cellular heterogeneity can be a major confounder in tissue
and cell culture comparison (Sandor et al., 2017), and could
represent an important source of inflated variance within
and between laboratories. To investigate variation in the
cellular composition of our iPSC-derived cell populations,
we generated the individual transcriptional profiles of
1,440 fluorescence-activated cell sorting (FACS)-sorted
iPSC-derived cortical neurons produced by two of five
participant laboratories (sites D and E for each of the two
cells lines at the FP + 55 time point; see Experimental
Procedures). After discarding low-quality cell libraries (see
Supplemental Experimental Procedures), 771 SC transcrip-
tomes were available for subsequent analysis.
Using unsupervised hierarchical clustering on the
expression profiles we identified four and five subpopula-
tions of cells within the SB808 and SBAD3 cell populations,
respectively (see Supplemental Experimental Procedures,
Figures 6A and S5A). The cortical differentiation protocol
we used has been extensively validated and efficiently pro-
duces high yields of cortical excitatory neurons as well as
astrocytes. We assessed the presence of neuron-, glial-,
and other cell-type-specific markers within each subpopu-Figure 5. Analyses of Factors Explaining the Unwanted Variance
(A) Increased reproducibility of gene expression difference between
showing high heterogeneity across sites before and after RUV based on
I2 threshold (Het_I2_75) (Top). Overlap of DE genes between cell lin
factors (Venn diagrams, bottom).
(B) Separation between the lines in singular value decomposition plo
covariates of interest before and after RUV.
(C) ‘‘Laboratory’’ is a major confounder corrected by RUV. Each bar sum
W_20) and explained by known potential confounders.
(D) Laboratory variance is correlated to several experimental variat
laboratory-specific RUV factors and known laboratory-specific potentia
in Supplemental Experimental Procedures section and in Figure S4B.
See also Figures S3 and S4.lation (see Supplemental Experimental Procedures). For
each line, we found that the largest cell subpopulation
was uniquely and significantly enriched in neuron-specific
markers (Figures 6A and S5A). The second largest subpopu-
lation was also enriched for a distinct set of neuron-specific
markers (cluster 2 for SB808 and SBAD3) (Figures 6A and
S5A). Other subpopulations were enriched in astrocyte
markers (e.g., clusters 3 and 4 for SB808 and cluster 4 for
SBAD3) (Figure S5).
While Shi et al. (2012b), who described the protocol,
observed astrocytes forming after day 45, we found here
(1) that glial cells represented a large proportion (20.8%),
(2) that the fraction of glial cells varied from site to site
(15% site D versus 21% site E), and (3) that the fraction
of glial cells was higher in the SB808 line than in the
SBAD3 line (29% SB808 versus 12% SBAD3).
Cellular Subpopulations Can Show Opposing
Differential Gene Expression and Introduce
Considerable Bias in Comparative Studies
The SC analysis revealed cell culture subpopulations of
differing proportions between two sites (Figure S5A) that
could affect the differential gene expression analysis. Inter-
estingly we found that subpopulations 2, 3, and 4 also
expressed a small number of genes representing oligoden-
drocyte or microglia markers (Figure 6A). The expression
of genetic markers of other cell types not intended to be
induced by our differentiation may represent either a
genuine developmental feature of these cells or an artifact
of in vitro differentiation, where the epigenetic silencing
of other cell type-specific genes is not fully effective––in
either case the heterogeneity could significantly bias differ-
ential gene expression between lines and between sites.
After discounting technical artifacts (e.g., plate effects),
we found that the DE genes and pathways varied signifi-
cantly between iPSC-derived subpopulations. Most
notably we observed that gene expression differences
between the two lines were negatively correlated between
subpopulations 1 and 6, and thus directly obscure theand Laboratory Heterogeneity
lines across laboratories after RUV correction. Number of genes
5% false discovery rate (FDR) threshold (Het_FDR_05) and on 75%
es across sites before and after removal of 5, 10, 15, and 20 RUV
ts helps explain the different number of DE genes between the two
marizes the proportions of variance captured by RUV factors (W_1 to
ions. The matrix shows the linear correlations between means of
l confounders plus neuron-astrocyte axis scores (NA_PC1) described
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(legend on next page)
906 Stem Cell Reports j Vol. 11 j 897–911 j October 9, 2018
detection of DE genes (Figure S5D). To evaluate how the re-
sults of DE analyses can be biased by the observed cell het-
erogeneity, we randomly sampled populations of 100 cells
from each line and observed the stability of DE genes and
pathways. Of 192 originally observed DE genes, only
10 genes (5%) that were associated with a very low p value
(<1020) were consistently reported with a false-negative
rate <5% (Figure S5B). This clearly demonstrated that cell
heterogeneity can yield a major bias in the comparison of
gene expression profiles between iPSC-derived cells and
that only the most significant DE genes are detectable
through the heterogeneity. Indeed, upregulated and down-
regulated DE genes for each laboratory in the bulk tran-
scriptomic studywere significantly overrepresented among
specific subpopulations of the SC study (upregulated in
subpopulation numbers 1, 2, and 3, and downregulated
in subpopulation numbers 1, 4, and 6, respectively, hyper-
geometric test; Tables S2 and S3; Figure S5C).
Cellular Composition Varies Both by Laboratory and
Cell Line upon Differentiation
Given the results obtained at the SC level, we askedwhether
the observed heterogeneity in cell identity (neuronal and
non-neuronal populations) could explain the variance in
the bulk transcriptomic data due to the test site. For this,
we used available RNA-seq data from purified human brain
cell types to identify gene expression variation associated
with cell type and extended the list of marker genes em-
ployed in the SC analyses (see Experimental Procedures).
Examining the variation between genotypes across all sites,
we found that the SBAD3 upregulated genes were enriched
in neuronalmarkers (p = 2.63 1018, after RUV correction),
while the SB808 upregulated genes were enriched in non-
neuronal markers (p = 3.2 3 1011 for astrocytes after RUV
correction). Furthermore, a clear separation by genotype
on principal components reflecting the above-mentionedFigure 6. Distinct Cellular Populations Are Identified within the
ferences in the Bulk Transcriptomic Comparisons
(A) Cellular heterogeneity in individual cells across cell lines and lab
distinct cellular populations in SB808 and SBAD3 lines in two labora
genes (see Supplemental Experimental Procedures).
(B) A neuron-astrocyte axis of gene expression variation illustrates c
oratories. The projection of before (top) and after (bottom) RUV c
neuronal-glia gene expression identity axis (top) shows that glia-neu
(C) Increase of neuron- and astrocyte-specific protein abundances at
Protein Atlas neuron-specific (top) and glia-specific (bottom) protein
(top). A significant increase of SYP is observed from FP + 25 to FP + 55
at different time points (bottom). A significant increase of FABP7 and
specifically shows an increase in all SB808 lines compared with SBAD
distributions, where the span of the box is the interquartile range (IQ
lower whiskers represent the data point with the maximum distance
1.5 3 IQR. Data beyond the end of the whiskers are outliers.
See also Figure S5.similarity of SBAD3 lines to neurons and of SB808 lines to
non-neuronal cells was evident when the samples were pro-
jected on the PCA coordinates of the human brain cell types
both before and after RUV correction (Figure 6B). However,
before RUV correction, there is significant systematic varia-
tion evident in the neuronal/non-neuronal composition in
the lines cultured by different laboratories following the
same protocol. Indeed, the neuronal/non-neuronal compo-
sition of the lines cultured by each laboratory is well-corre-
lated with the ‘‘laboratory’’ contribution to RUV factors 1,
8, and several other factors (Figure 5D). Thus, the predisposi-
tion of each line toward generating cell populations with
distinct proportions of neurons and non-neuronal cells is
an important driver of gene expression differences between
the two cell lines at the bulk transcriptome level. This is also
reflected at the protein level, whereby glial marker proteins
(FABP7 and GFAP) showed increased abundance at the
FP + 55 time point and that GFAP is more abundant in
SB808 samples than in SBAD3 samples for all laboratories
(Figure 6C). Interestingly, variation in neuronal/non-
neuronal composition of the two lines did not increase
from the early to the later time point when we
explainedRUVfactors throughknowncovariates (Figure5C)
and compared Euclidean distances between time points
(Figure S1A).DISCUSSION
In this study we examined the reproducibility of a long-
term neuronal differentiation protocol undertaken in five
laboratories. Further, we also intended to identify ‘‘hidden’’
factors important to a robust method and quantify the
extent to which they contribute to experimental variation
in molecular data. We therefore focused on repeated differ-
entiations of two lines with different genetic backgroundsiPSC-Derived Neuronal Populations That Potentially Drive Dif-
oratories. The heatmap of single-cell transcription data reveals six
tories according to their expression of a set of cell identity marker
ell type is a major contributor to cell line variation across all lab-
orrection bulk transcriptomic expression patterns (FP + 55) onto
ronal identity contributes to the expression variation (bottom).
later time points in all laboratories. Protein abundance of Human
s. Protein abundances of a neuron marker at different time points
time point (p < 0.05). Protein abundances of two astrocyte markers
GFAP is observed from FP + 25 to FP + 55 time points (p < 0.05). GFAP
3 lines within each laboratory. Box-and-whisker graphs represent
R) and includes the median (bold line). The ends of the upper and
from the third and first quartiles, respectively, but no further than
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to assess whether it was possible to consistently distinguish
two iPSC lines after neuronal differentiation, using molec-
ular readouts. In our multi-center experiment, we deliber-
ately chose not to investigate multiple disease and control
donor lines in order to focus on reproducibility rather than
identifying novel disease phenotypes. With a detailed and
shared protocol applied across all partner laboratories, we
controlled variability in the differentiation process to the
extent it is usually disclosed in published protocols, while
expecting variation between the cell lines due to their
differing genotypes (the sum of all other potential ge-
netic/epigenetic differences between the two lines), as
well as originating from specific laboratory practices not
harmonized across test sites.
Our approach found (1) that genotype-driven gene
expression variation is detectable by a laboratory in partic-
ular when within-laboratory consistency is high; (2) that
genotypic effects are masked in aggregated molecular data
frommultiple laboratories due to site-specific confounders;
(3) that cell-type compositional heterogeneity varied both
by laboratory and by cell line, and contributed significantly
to themasking of genotypic effects inmulti-site studies; (4)
that prolonged cell culture after FP did not significantly
increase inter-laboratory variance and that much of the
cell-type compositional heterogeneity was likely deter-
mined during neural patterning and shortly after FP; and
(5) that normalization methods were able to remove
nuisance site-specific effects to reveal biological signals
including genotypic effects. Our study therefore under-
scores the importance of recognizing, recording and report-
ing experimental variables, and, where possible, using
appropriate statistical methods to remove unwanted vari-
ability, in order to generate more reproducible molecular
studies based on differential gene and protein expression
phenotypes.
The application of in vitro human disease models using
iPSC lines is a potentially transformative approach for un-
derstanding disease mechanisms, novel target discovery,
and personalized medicine. Unsurprisingly, the majority
of efforts have been on monogenic forms of disease where
there are strong genotype-phenotype relationships due to
large effect sizes of the gene mutation. The expectation
for such disorders is that, at a cellular level, highly pene-
trant mutations would cause easily detectable in vitro mo-
lecular and cellular phenotypes. Although not the focus
of our study, when we examined the biochemical pheno-
type in line SB808, which carried a familial Alzheimer’s
disease mutation in the PS1 gene, we did indeed detect a
highly robust change in specific b-amyloid peptide ratios
(Szaruga et al., 2015) when compared with the iPSC line
without the PS1 mutation (Figure S6). This strong cross-
site reproducibility has likely been observed because (1)
the altered production of b-amyloid peptides is proximal908 Stem Cell Reports j Vol. 11 j 897–911 j October 9, 2018to the PS1 mutation, and (2) is due to the robustness of
the ratio-based readout.
The molecular analysis by contrast showed very little
overlap between sites despite the detailed, shared protocol,
and attempts to minimize technical variability, including
processing and analyzing omics samples at the same labo-
ratories, enabling us to focus on the differentiation pro-
cess-related confounders. Within a laboratory, there was
much less variance, and gene expression profiles of the
two lines clearly segregated even before RUV analysis.
Two sites, C and D, showing low levels of dispersion be-
tween replicates, produced a large number of genes that
were significantly differentially expressed. When consid-
ering all 5 sites, only 15 genes were consistently different
between the two cell lines prior to normalization,
compared with over 200 genes mutually detected after fac-
tor analysis-based removal of the unwanted variation. The
pre-RUVoverlap of the DE genes of sites C and D was quite
high, but much of this overlap may have been artifactual,
since for site C the number of DE genes fell from 7,524 to
3,354 after removing 5 factors, and to 1,480 genes after
removing 20 factors. This suggests that a laboratory could
generate ‘‘private’’ gene expression lists with high confi-
dence based upon highly significant p values as in our
study, but, unless sources of variance are explored, it is
difficult to knowwhether suchDE lists are biologically rele-
vant. This is important because molecular studies by indi-
vidual laboratories are often used to generate hypotheses
for further investigations, and therefore our study raises
significant concerns that many of the detected DE genes
can be an artifactual.
Addressing this concern, our work found that, despite the
numerous sources of potential confounders, it is possible to
detect consistently replicated signals if there is a sufficient
number of samples to power an appropriate statistical
approach and due consideration is given to complexity of
iPSC-differentiated cell cultures. The presence of multiple
cellular subpopulations differing between two labs was
confirmed by the SC transcriptome study. Strikingly, we
observed that differential gene expressionpatterns between
the two cell lines in one cellular subpopulations can have
the opposite pattern in another subpopulation. We found
that, in a simulated heterogeneous bulk transcriptome
based on our SC data, only the most significant and stron-
gest gene expression (p < 1020) differences between the
two cell lines were detectable. The differing propensity in
cellular fates of the two iPSC lines produced by our stan-
dardized differentiation protocols was evident in the bulk
transcriptome data both before and after removing
unwanted variation, demonstrating systematic variation
in culture cellular composition associated with both geno-
type and laboratory. More rigorous quality control of
cellular composition upon differentiation at a series of
intermediary time points may help improve the consis-
tency of results between laboratories. However, we also
found that different subpopulations within a culture can
be characterized by aberrant expression of cell identity
markers from cell types that are not present in the culture
such asmicroglia or oligodendrocytes. Immunohistochem-
istry or functional studies such as calcium imaging or elec-
trophysiology may not reveal these cell subpopulations.
These cells may therefore represent a potentially important
cause of variance thatwill be hidden to quality controlmea-
sures unless these include SCprofiling.Altogether our study
shows that cellular heterogeneity can introduce significant
bias in differential gene expression experiments and likely
represents themajor contributor to inflatingwithin-labora-
tory variance and to inter-laboratory variability.
One of the important aspects of our study was to identify
those factors which are correlated to the RUV factors,
potentially explaining the increased cross-site variability.
Not surprisingly, our computational analysis indicated
that SITE (i.e., laboratory) is the most influential source of
variation (explaining between 40% and 60% of the vari-
ance in the first 4 RUV factors), followed by the practice
of starting the differentiation of progenitors on different
days as opposed to plating on the sameday. To further iden-
tify the sources of inter-laboratory variability, we correlated
site-specific variation in RUV factors to experimental
practices known to be different for the various test sites.
This analysis allowed us to pinpoint experimental variables
which were highly correlated to several RUV factors, and
potentially hampered cross-site reproducibility. Among
these were a number of factors, some of which are often
not disclosed in published differentiation protocols, such
as iPSC passage number before differentiation, the number
of passages before FP, media volume changes, feeding at
weekends, and use of frozen neural progenitor cells.
Many of these factors likely alter the epigenetic and cellular
programs that determine progenitor cell fate choices,
including neuronal-glial balance to thereby contribute to
the heterogeneity and variance. Based on our study we
strongly suggest that these should be a standard part of
every published differentiation protocol to increase the
chance of robust reproducibility of iPSC-based studies.
Reproducibility in biomedical science is a major cause of
concern and has impacted the pharmaceutical industry,
where study reproducibility is a pre-requisite for target dis-
covery, assay development, and a successful drug discovery
program. The potentially underlying causes for the lack
of reproducibility have been extensively scrutinized and
attributed to factors such as poor study design and inappro-
priate statistical methods, as well as the culture of grant
funding and publication biases. Moreover, as our paper
illustrates, an individual laboratory conducting hypotheses
generating molecular studies, without external reference,or further validation studies cannot know whether their
significant differential gene findings are due to a systematic
bias in their laboratory or arising from the biological condi-
tion under study. It is therefore critical that any potential
hypotheses are validated including through the use of liter-
ature evidence and increasingly available complementary
datasets such as human brain tissue and animal model
studies. Collaborative approaches, especially large public-
private partnerships involving multiple test centers,
if carefully designed, offer a powerful solution to per-
forming studies which yield reproducible mechanistic
insights. These multi-center experiments also reveal
important learnings for the individual laboratories by
identifying experimental practices to be disclosed when
publishing iPSC differentiation protocols to increase their
reproducibility.
In our paper, we have shown that, while cellular hetero-
geneity of the iPSC cultures differentiated at various labora-
tories arising from site-specific practices as well as other
cryptic factors can mask almost all biological effects, these
confounders can be identified and overcome. The compu-
tational biology approaches employed here revealed and
removed the site-specific biases, enabled access to the un-
derlying biology, and identified publication best practices.EXPERIMENTAL PROCEDURES
See further details in the Supplemental Experimental Procedures.
Generation and Maintenance of STEMBANCC iPSC
Lines
The human iPSC lines SBAD3-1 and SB808-03-04 (the latter
carried the Alzheimer’s disease-related PS1 intron 4 mutation)
were derived from human skin biopsy fibroblasts following
signed informed consent, with approval from the UK NHS
Research Ethics Committee (REC: 13/SC/0179) and were derived
as part of the IMI-EU sponsored StemBANCC consortium. iPSC
generation was performed using the CytoTune-iPS 2.0 Sendai
Reprogramming Kit (A16517) from Thermo Fisher Scientific
(Waltham, MA).
Bulk Transcriptomic Experiment
For transcriptomic analyses, 12 samples were generated in each
laboratory: 3 replicates of the SBAD3 cell line and 3 replicates of
the SB808 cell line at each of the 2 time points (Figure 1A). Two
samples were excluded from analysis due to problems during the
differentiation process and another one because of a contamina-
tion issue during RNA-seq, leading to a total of 57 samples being
available for transcriptomic analysis.
SC RNA-Seq Experiment
SC Isolation
SC suspensions were generated using Accutase dissociation fol-
lowed by SCfiltration of iPSC-derived cortical neurons. The successStem Cell Reports j Vol. 11 j 897–911 j October 9, 2018 909
of the suspension was manually confirmed on a hemocytometer.
The SC suspension was sorted into a 96-well PCR plate containing
a lysis mix. Sorting gates were set to include only live (DAPI-nega-
tive) single cells. Stream alignment and sort efficiency was checked
using Accudrop beads (Becton Dickinson).
SC RNA-Seq Library Preparation and Sequencing
Single iPSC-derived cortical neurons were isolated by FACS onto
96-well plates in 2 mL lysis buffer (Trombetta et al., 2014). Each
plate included 4 bulks, each obtained by extracting total RNA
from 4,000 cells using RNeasy Micro Kit (QIAGEN) and using
1/14th of the extracted RNA solution. Libraries were prepared
following the Smart-Seq2 protocol described by Picelli et al.
(2013) and Trombetta et al. (2014). Each sample was spiked with
the equivalent of 1 mL of 1:10,000,000 dilution of the ERCC RNA
Spike-In Mix 1 (Thermo Fisher Scientific). Libraries were pooled
in 288- or 384-plexes and each pool sequenced on 1 lane of HiSeq
4000 at 75 bp paired end.
Proteomics
Proteomic Sample Processing, Measurement, and Data
Analysis
Cells from three wells were detached in ice-cold PBS, pooled, and
snap frozen for proteomics analysis. Prior to digestion, cell pellets
were dissolved in lysis buffer, and obtained lysates were pooled
from triplicate wells, replicated to increase the number of detect-
able proteins leading to a total of 20 samples for subsequent
analysis, and spun at 1,0003 g. Sampleswere subject to in-solution
proteolytic tryptic digestion and analyzed using 2D-LC-MS.
Proteins were identified using Waters ProteinLynx Global server
v.3.0.1 and Progenesis Bioinformatic software (non-linear dy-
namics) as described previously (Heywood et al., 2015).
ACCESSION NUMBERS
The accession number for the transcriptomic data reported in this
paper is GEO: GSE118735.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, six figures, and six tables and can be found with this
article online at https://doi.org/10.1016/j.stemcr.2018.08.013.
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